Streetbeat News

FTHWF

Field Trip Health & Wellness Ltd

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Reunion Neuroscience (NASDAQ:REUN) is set to go private following a final court approval. The company is closing on its take-private transaction with MPM BioImpact affiliates, with shareholders approving the arrangement plan. The acquisition of Reunion in an all-cash transaction of $13.1 million is expected to close on or about July 21, 2023. Reunion was split from Field Trip Health in mid-2022 and has been developing a novel serotonergic psychedelic compound, RE104, as a potential treatment for postpartum depression.

Portfolio Pulse from Lara Goldstein

July 17, 2023 | 9:04 pm

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver, attracting over 12,000 attendees. New York Mets owner Steve Cohen announced a $5 million grant for MAPS’ ongoing clinical studies toward FDA approval of MDMA-assisted therapy for PTSD. Toms Shoes founder Blake Mycoskie pledged to donate and invest $100 million in organizations and projects advancing psychedelic-assisted therapies. SEMRush (NYSE:SEMR) analysis revealed a shift in America's consciousness towards psychedelics and cannabis. Several companies received regulatory approvals and patents, and announced partnerships and financial results.

Portfolio Pulse from Lara Goldstein

July 04, 2023 | 2:21 pm

Reunion Neuroscience Inc. (NASDAQ:REUN) reported Q4 and full year 2023 financial results, showing a decrease in cash and cash equivalents, increased R&D and G&A expenses, and a net loss from continuing operations. The company's lead asset RE104 showed promising results in a Phase 1 analysis for the treatment of Postpartum Depression. Reunion also announced a take-private transaction by MPM BioImpact valued at approximately $13.1 million. The company faces financial risks including future expenses and expected losses, and IP risks including ongoing litigation with Mindset Pharma (OTC:MSSTF).

Portfolio Pulse from Lara Goldstein

June 29, 2023 | 5:22 pm

PharmaTher Holdings Ltd. has filed a pre-submission facility correspondence for its novel racemic ketamine KETARX to the FDA, aiming for an expedited review. The company expects KETARX approval in Q1 2024 and a U.S. commercial launch in Q2 2024. Meanwhile, mental healthcare treatment provider Stella has acquired Field Trip’s U.S. assets to expand its treatment offerings. The acquisition will allow Stella to assume operations of Field Trip clinics in New York and Washington D.C.

Portfolio Pulse from Lara Goldstein

June 27, 2023 | 10:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.